Display options
Cite
Karve S, Lorenzo M, Liepa AM, et al. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. J Gastric Cancer. 2015;15(2):87-104doi: 10.5230/jgc.2015.15.2.87.
Karve, S., Lorenzo, M., Liepa, A. M., Hess, L. M., Kaye, J. A., & Calingaert, B. (2015). Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. Journal of gastric cancer, 15(2), 87-104. https://doi.org/10.5230/jgc.2015.15.2.87
Karve, Sudeep, et al. "Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database." Journal of gastric cancer vol. 15,2 (2015): 87-104. doi: https://doi.org/10.5230/jgc.2015.15.2.87
Karve S, Lorenzo M, Liepa AM, Hess LM, Kaye JA, Calingaert B. Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database. J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30. PMID: 26161282; PMCID: PMC4496446.
Copy Download .nbib Format: NLM
Share it on

J Gastric Cancer. 2015 Jun;15(2):87-104. doi: 10.5230/jgc.2015.15.2.87. Epub 2015 Jun 30.

Treatment Patterns, Costs, and Survival among Medicare-Enrolled Elderly Patients Diagnosed with Advanced Stage Gastric Cancer: Analysis of a Linked Population-Based Cancer Registry and Administrative Claims Database.

Journal of gastric cancer

Sudeep Karve, Maria Lorenzo, Astra M Liepa, Lisa M Hess, James A Kaye, Brian Calingaert

Affiliations

  1. RTI Health Solutions, Research Triangle Park, NC, USA.
  2. Eli Lilly and Company, Windlesham, Surrey, UK.
  3. Eli Lilly and Company, Indianapolis, IN, USA.

PMID: 26161282 PMCID: PMC4496446 DOI: 10.5230/jgc.2015.15.2.87

Abstract

PURPOSE: To assess real-world treatment patterns, health care utilization, costs, and survival among Medicare enrollees with locally advanced/unresectable or metastatic gastric cancer receiving standard first-line chemotherapy.

MATERIALS AND METHODS: This was a retrospective analysis of the Surveillance, Epidemiology, and End Results-Medicare linked database (2000~2009). The inclusion criteria were as follows: (1) first diagnosed with locally advanced/unresectable or metastatic gastric cancer between July 1, 2000 and December 31, 2007 (first diagnosis defined the index date); (2) ≥65 years of age at index; (3) continuously enrolled in Medicare Part A and B from 6 months before index through the end of follow-up, defined by death or the database end date (December 31, 2009), whichever occurred first; and (4) received first-line treatment with fluoropyrimidine and/or a platinum chemo-therapy agent.

RESULTS: In total, 2,583 patients met the inclusion criteria. The mean age at index was 74.8±6.0 years. Over 90% of patients died during follow-up, with a median survival of 361 days for the overall post-index period and 167 days for the period after the completion of first-line chemotherapy. The mean total gastric cancer-related cost per patient over the entire post-index follow-up period was United States dollar (USD) 70,808±56,620. Following the completion of first-line chemotherapy, patients receiving further cancer-directed treatment had USD 25,216 additional disease-related costs versus patients receiving supportive care only (P<0.001).

CONCLUSIONS: The economic burden of advanced gastric cancer is substantial. Extrapolating based on published incidence estimates and staging distributions, the estimated total disease-related lifetime cost to Medicare for the roughly 22,200 patients expected to be diagnosed with this disease in 2014 approaches USD 300 millions.

Keywords: Claims data; Costs; Gastric cancer; Survival; Treatment patterns

References

  1. Am J Clin Oncol. 2004 Oct;27(5):477-80 - PubMed
  2. Hepatogastroenterology. 1999 Mar-Apr;46(26):1206-13 - PubMed
  3. Eur J Cancer. 2011 Oct;47(15):2306-14 - PubMed
  4. J Clin Oncol. 2012 May 1;30(13):1513-8 - PubMed
  5. J Clin Oncol. 2006 Nov 1;24(31):4991-7 - PubMed
  6. Anticancer Res. 2011 Oct;31(10):3543-54 - PubMed
  7. Oncologist. 2005;10 Suppl 3:49-58 - PubMed
  8. J Natl Cancer Inst. 2007 Jan 3;99(1):14-23 - PubMed
  9. J Clin Oncol. 2002 Jan 1;20(1):173-8 - PubMed
  10. Gastric Cancer. 2006;9(1):14-8 - PubMed
  11. Oncologist. 2004;9 Suppl 2:9-15 - PubMed
  12. Med Care. 2002 Aug;40(8 Suppl):IV-3-18 - PubMed
  13. Ann Oncol. 2013 Nov;24(11):2850-4 - PubMed
  14. Am J Manag Care. 2008 May;14(5):297-306 - PubMed
  15. Cancer Epidemiol Biomarkers Prev. 2014 May;23(5):700-13 - PubMed
  16. Med Care. 2002 Aug;40(8 Suppl):IV-55-61 - PubMed
  17. J Health Serv Res Policy. 2003 Apr;8(2):75-82 - PubMed
  18. J Clin Oncol. 2004 Dec 15;22(24):4971-8 - PubMed
  19. Gastric Cancer. 2015 Apr;18(2):360-7 - PubMed
  20. Med Care. 2002 Aug;40(8 Suppl):IV-49-54 - PubMed
  21. Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7 - PubMed
  22. Ann Surg Oncol. 2013 Jul;20(7):2124-31 - PubMed
  23. Cancer. 2006 Dec 1;107(11):2581-8 - PubMed
  24. World J Gastroenterol. 2009 Jun 14;15(22):2689-92 - PubMed
  25. J Hematol Oncol. 2009 Feb 23;2:9 - PubMed
  26. Jpn J Clin Oncol. 2007 Dec;37(12):936-41 - PubMed
  27. Value Health. 2009 Jun;12 (4):481-8 - PubMed
  28. J Clin Epidemiol. 2008 Dec;61(12):1234-40 - PubMed
  29. Med Care. 2002 Aug;40(8 Suppl):IV-104-17 - PubMed
  30. Med Care. 2002 Aug;40(8 Suppl):IV-43-8 - PubMed
  31. Hepatogastroenterology. 2011 Jan-Feb;58(105):208-12 - PubMed
  32. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29 - PubMed

Publication Types